Revelation Biosciences Reports $3.3 Million Third-Quarter Net Loss

Revelation Biosciences reported a net loss of $3.3M for Q3 2026, with operating expenses rising to $3.4M from $1.9M in Q3 2025. The company has $9.1M in cash, expected to fund operations into Q2 2027. It is developing Gemini for kidney diseases and infections, with a potential $94B market according to an independent assessment.

Original reporting
Published Nov 5, 2026, 10:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 10:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Revelation Biosciences Reports $3.3 Million Third-Quarter Net Loss — source image
Decision brief

The 30-second read

$REVBBearishLow
01

Why it matters

The disclosed loss and cash position suggest near‑term financing risk, but the large TAM for Gemini may attract future capital.

02

Market read

Quarterly earnings of a micro‑cap biotech; limited broader market impact but important for niche investors.

03

What to watch

Potential partnership or grant funding for Gemini could improve cash runway beyond current estimates.

Relevance 6/10Novelty 6/10Timing: post‑market release today

Background

Revelation Biosciences is a clinical‑stage biotech developing the Gemini platform for kidney‑related conditions.

Company-level read

Ticker impact

$REVBBearishHigh confidence
Context

Revelation Biosciences disclosed its Q3 2026 net loss of $3.3M and cash runway to Q2 2027 in an 8‑K filing.

Expected impact

likely downward pressure as investors price in cash constraints

Evidence & confidence

Quarterly loss exceeds prior year and cash balance is modest, indicating near‑term financing risk.

Market effects

Highlights funding challenges for early‑stage biotech firms developing kidney‑injury therapies.

Minimal, limited to U.S. biotech micro‑cap segment.

Low, as the company is a small cap with niche focus.

Counterpoint

If the $94B addressable market for Gemini materializes, the stock could rebound on future milestones.

Key entities

  • Revelation Biosciences

    Biotech firm developing Gemini therapy platform.

Related articles

$REVBLow

Revelation Biosciences, Inc. Announces Financial Results

REVELATION BIOSCIENCES, INC. (REVB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Revelation Biosciences, Inc. Announces Financial Results For the Three and Nine Months Ended September 30, 2026 SAN DIEGO – November 5, 2026 – Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developi

$REVBMedAI 8/10

Revelation Aiming for Paradigm Shift in Kidney Disease Care

Revelation Biosciences (REVB) is developing Gemini, a drug candidate for acute and chronic kidney disease, post-surgical infections, and severe burns. The company plans to launch a Phase 2/3 study for acute kidney injury later this year, with completion expected in about two years. CEO James Rolke highlights Gemini's potential to reduce inflammation and prevent scar tissue, citing positive pre-clinical and early clinical results. Revelation aims to submit Gemini for FDA approval if the study mee

$REVBMed

Revelation Biosciences, Inc. Announces Financial Results

REVELATION BIOSCIENCES, INC. (REVB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Revelation Biosciences, Inc. Announces Financial Results For the Three and Six Months Ended June 30, 2026 SAN DIEGO – August 6, 2026 – Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developing innov

$XPMedAI 8/10

XP Q3 2026 slides: asset growth strong, but margin pressure evident

XP Inc. reported Q3 2026 earnings with total client assets up 15% YoY to R$2.2T, but net margins contracted to 26.9%. Revenue grew 8% YoY to R$5.3B, while SG&A expenses rose 12% YoY. Shares fell 4.26% post-earnings. The company is diversifying revenue, with non-investment revenues now 20% of retail revenue. Management expects 10% annual top-line growth in 2027.

$LUVUMed

Luvu Brands, Inc.: Luvu Brands Reports First Quarter Fiscal 2027 Results: 10% Net Sales Growth, Wholesale Sales Up 12%

Luvu Brands (LUVU) reported Q1 FY2027 results with net sales up 10% to $6.78M, wholesale sales up 12.3% to $4.72M, and direct-to-consumer sales up 5.3% to $2.06M. Gross profit fell 10.1% to $1.78M due to higher freight and labor costs, resulting in an operating loss of $332K and a net loss of $365K. Cash from operations increased to $120K, and cash reserves were $1.02M.